Gregory J. Bullington

Co-Founder & CEO

Greg Bullington is co-founder and CEO of Magnolia Medical Technologies. He has led all commercial aspects of company development since inception including clinical trial design and execution, peer-reviewed publication, product development, manufacturing, commercial launch and overall intellectual property strategy. To date, Greg has raised over $30 million in capital to drive the successful growth and development of the company.

Greg has extensive experience in the healthcare industry having led product commercialization and strategy engagements for a wide variety of companies in the biotech (novel immunotherapy), healthcare insurance, wellness and enterprise software sectors.

Greg began his career in professional services with the Audit & Assurance practice of Deloitte & Touche LLP. He continued his professional development as a management consultant with Lake Partners, a Seattle-based strategy firm. In 2006, Greg founded Forum Ventures, a technology commercialization consultancy focused on accelerating the growth of early and mid-stage technology companies.

Over the past 15 years, Greg has led engagements and worked with senior executive teams at over 50 companies ranging from Fortune 100 corporations to venture-backed and early stage startups as a consultant, advisor, and investor. Additionally, Greg has significant intellectual property expertise and is the first named inventor on 28 issued patents as well as over 50 pending US and international patent applications.

Richard G. Patton, M.D.

Co-Founder & Medical Director

Dr. Patton is a board-certified pathologist with more than 40 years of active practice experience. Recognizing the patient safety and financial implications of false positive blood cultures, he has long been interested in exploring opportunities to reduce contamination rates.

In 2006, Dr. Patton designed a clinical trial to test the effectiveness of Initial Specimen Diversion Technique (ISDT), an innovation that he conceived earlier in his career. The results of the trial were significantly positive and published in the peer-reviewed Journal of Clinical Microbiology.

Dr. Patton’s areas of expertise are clinical microbiology, gastrointestinal pathology, and cytopathology. He was the Chief of Pathology and Medical Director of Clinical Laboratories at Northwest Hospital, Seattle, Washington for four decades. He has served as a Laboratory Inspector, Washington State Commissioner, NW Regional Commissioner, and Accreditation and Complaints Committee Member for the College of American Pathologists Laboratory Accreditation Program.

Robert E. Gerberich

Chief Commercial Officer

Bob Gerberich is a results-driven global business leader with over 25 years of experience in the surgical and medical device segments of the life sciences market. As a senior sales and marketing executive, he has an exceptional track record of success building new markets and driving rapid commercial growth from product introduction through broad scale adoption. Bob joined Magnolia Medical Technologies as Chief Commercial Officer in April 2017. He is responsible for leading all commercial and customer facing functions of the company.

Most recently, Bob served as Vice President of Sales and Marketing and Vice President of Sales at Invuity, Inc. (NASDAQ: IVTY). Under his direct commercial leadership, Invuity transformed into a rapid growth direct sales-driven advanced surgical photonics company leading the advancement of open minimal access surgery. Bob led the company from a $3 million to $50 million revenue run rate, delivering 17 consecutive quarters of quarter-over-quarter sales growth. He also drove the creation, launch and implementation of strategic marketing and partnership programs. The commercial impact of these programs supported the successful Initial Public Offering (IPO) of the company in June of 2015.

Prior to Invuity, Bob served as President of UltraShape North America and Head of Global Sales for UltraShape Ltd (acquired by Syneron Medical Ltd. [NASDAQ: ELOS]), where he established the North American subsidiary for UltraShape and launched the first non-surgical focused ultrasound body sculpting technology in the world.

Before UltraShape, Mr. Gerberich was Vice President of Sales and Marketing and Vice President of Sales for Thermage, Inc. (now Solta Medical, a division of Valeant Pharmaceuticals [NYSE:VRX]), where he led the successful platform launch of a proprietary radiofrequency technology, creating a new market for non-invasive tissue tightening. He built a direct sales organization from the ground up and led the company from $0 to a $50 million revenue run rate.

Earlier in his career, Bob led dynamic and fast growing sales organizations at several other medical device companies within the hospital markets including INAMED Aesthetics, acquired by Allergan (NYSE: AGN), LySonix Inc., acquired by Mentor Worldwide, division of J&J (NYSE: JNJ), Leibinger L.P. acquired by Stryker (NYSE: SYK)], and Davol Inc. Blood Mgmt. Group subsidiary of CR Bard (NYSE: BCR). Mr. Gerberich holds a B.S. in Marketing from Illinois State University.

Jay Schwartz

Vice President, Strategy & Business Development

Jay brings a broad range of strategy and hands-on experience to Magnolia Medical Technologies in his role to help set the strategic and operating direction of the company while also supporting the overall business development effort. Initially working with the company since 2015 as an advisor, Jay joined Magnolia full time in the middle of 2016.

Prior to Magnolia Medical, Jay’s healthcare experience includes leading Sales, Account Management, Strategic Partner and Corporate Development efforts for a leading healthcare information technology and content company. In addition, he worked with many healthcare clients across the payer, provider, technology and device segments in his nearly 15 years of consulting experience.

His career includes a mix of professional services and operating leadership positions including consulting work with Bain, McKinsey and Lake Partners as well as operating roles with Procter & Gamble, PACCAR, Cintas and Milliman Care Guidelines. Jay has a Finance degree from Notre Dame and an MBA from Stanford.